This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Snap files answer in US case alleging it encouraged illicit drug sales

( May 12, 2025, 22:23 GMT | Official Statement) -- MLex Summary: Snap filed its answer to claims from parents of kids who died of fentanyl overdoses that the company turned a blind eye to the drug crisis and even created an online haven for drug dealers. “Discovery into the facts underlying this case is now underway and will explore in detail the unfortunate circumstances of each person’s death or injury and the factors that contributed to it. But already it has become apparent that plaintiffs’ counsel’s core allegation — that the decedents would never have used drugs or obtained the deadly pill but for Snapchat — is baseless,” the company said in its answer. See attached filing....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login